Soros Fund Management LLC Purchases New Position in Pfizer, Inc. (PFE)

Soros Fund Management LLC purchased a new position in shares of Pfizer, Inc. (NYSE:PFE) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 31,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,067,000.

Several other hedge funds also recently modified their holdings of the company. New England Asset Management Inc. increased its stake in shares of Pfizer by 27.9% during the 1st quarter. New England Asset Management Inc. now owns 150,483 shares of the biopharmaceutical company’s stock worth $5,149,000 after purchasing an additional 32,867 shares during the last quarter. Day & Ennis LLC increased its stake in shares of Pfizer by 1.9% during the 1st quarter. Day & Ennis LLC now owns 28,986 shares of the biopharmaceutical company’s stock worth $992,000 after purchasing an additional 531 shares during the last quarter. Paulson & CO. Inc. increased its stake in shares of Pfizer by 15.7% during the 1st quarter. Paulson & CO. Inc. now owns 407,500 shares of the biopharmaceutical company’s stock worth $13,941,000 after purchasing an additional 55,300 shares during the last quarter. Signaturefd LLC increased its stake in shares of Pfizer by 52.3% during the 1st quarter. Signaturefd LLC now owns 38,055 shares of the biopharmaceutical company’s stock worth $1,302,000 after purchasing an additional 13,064 shares during the last quarter. Finally, Sii Investments Inc. WI increased its stake in shares of Pfizer by 1.6% during the 1st quarter. Sii Investments Inc. WI now owns 161,061 shares of the biopharmaceutical company’s stock worth $5,508,000 after purchasing an additional 2,573 shares during the last quarter. Institutional investors own 69.09% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://sportsperspectives.com/2017/09/10/soros-fund-management-llc-purchases-new-position-in-pfizer-inc-pfe.html.

Pfizer, Inc. (NYSE PFE) traded up 0.32% on Friday, hitting $34.10. 15,442,446 shares of the stock were exchanged. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $34.75. The firm has a market cap of $202.80 billion, a P/E ratio of 24.95 and a beta of 1.00. The company has a 50-day moving average of $33.36 and a 200 day moving average of $33.49.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.64 earnings per share. Equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.75%. Pfizer’s payout ratio is 94.12%.

Several equities research analysts have recently issued reports on PFE shares. Citigroup Inc. lowered shares of Pfizer from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $38.00 to $36.00 in a research note on Thursday, July 20th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Morgan Stanley restated a “neutral” rating and set a $35.00 price target (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Finally, ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $37.61.

In related news, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the transaction, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at $19,730,812. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders have sold 426,291 shares of company stock valued at $14,475,911 over the last ninety days. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply